NASDAQ:NBRV
Delisted
Nabriva Therapeutics AG Stock News
$1.42
+0 (+0%)
At Close: Nov 24, 2023
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Open
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
11:51am, Wednesday, 22'nd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Ar
UroGen Makes Chief Commercial & Chief Development Officer Promotions
12:23am, Thursday, 16'th Apr 2020
UroGen Pharma (NASDAQ:]) has added two of its senior employees to the C-suite. The Princeton, NJ-based company, which Wednesday received FDA approval of
Evercore bearish on medical device makers in premarket analyst action
11:32am, Thursday, 09'th Apr 2020
Inspire Medical Systems (NYSE:INSP) initiated with Overweight rating and $74 (19% upside) price target at Piper Sandler.Prevail Therapeutics (NASDAQ:PRVL) initiated with Overweight rating and $20 (46%
Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on Zosano Pharma (
ZSAN
–
Research Report
), Principia Biopharma (
PRNB
–
Research Report
) and Nabriv
Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETA
11:00am, Thursday, 09'th Apr 2020
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that the
Analysts Offer Insights on Healthcare Companies: Aeglea Biotherapeutics (NASDAQ: AGLE) and Nabriva (NASDAQ: NBRV)
03:14pm, Wednesday, 08'th Apr 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aeglea Biotherapeutics (AGLE
Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
11:00am, Wednesday, 08'th Apr 2020
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted
Nabriva (NBRV) Looks Good: Stock Adds 5.7% in Session
02:08pm, Thursday, 02'nd Apr 2020
Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Berenberg sees 93% upside in Alnylam in premarket analyst action
11:34am, Thursday, 19'th Mar 2020
Alnylam Pharmaceuticals (NASDAQ:ALNY) initiated with Buy rating and $200 (93% upside) price target at Berenberg.Dicerna Pharmaceuticals (NASDAQ:DRNA) initiated with Buy rating and $35 (160% upside) pr
Benzinga's Top Upgrades, Downgrades For March 17, 2020
01:33pm, Tuesday, 17'th Mar 2020
Upgrades * Morgan Stanley changed the rating for Westinghouse Air Brake Technologies Corp (NYSE: WAB) from Equal-Weight to Overweight. For the fourth quarter, Westinghouse Air Brake had an EPS of $1
BMO likes Blueprint Medicines in premarket analyst action
11:31am, Tuesday, 17'th Mar 2020
Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Neutral rating and $45 (107% upside) price target at Goldman Sachs.Ocular Therapeutics (NASDAQ:OCUL) initiated with Buy rating and $8 (97% upside
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sientra (
SIEN
–
Research Report
), Nabriva (
NBRV
–
Research Report
) and Galmed Pharmaceuticals (
Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights
08:01pm, Thursday, 12'th Mar 2020
-Prioritizing community opportunity for oral XENLETA given broad reimbursement coverage- -Reducing balance sheet risk through early paydown of a substantial portion of Hercules.
Nabriva Therapeutics Plc to Host Earnings Call
06:30pm, Thursday, 12'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Nabriva Therapeutics Plc (NASDAQ:NBRV) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at
